Jasper Therapeutics, Inc. (JSPR) 10-Year Financial Performance & Capital Metrics

JSPR • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutJasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.Show more

Revenue $0
EBITDA -$75M -10.5%
Net Income -$71M -10.6%
EPS (Diluted) -4.89 +20.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -101.73% +9.7%
ROIC -
Debt/Equity 0.03 -17.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.4x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 7 (bottom 7%)
✗Shares diluted 39.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-43.27%

EPS CAGR

10Y-

5Y-

3Y-

TTM-24.47%

ROCE

10Y Avg-79.53%

5Y Avg-91.7%

3Y Avg-98.5%

Latest-103.6%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-
Operating Expenses+	4.71M	20.68M	36.83M	51.2M	68.86M	76.24M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	1.09M	4.8M	11.41M	16.57M	17.08M	20.42M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	3.62M	15.88M	25.42M	34.63M	51.78M	55.82M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-4.71M	-20.68M	-36.83M	-51.2M	-68.86M	-76.24M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-3.39%	-0.78%	-0.39%	-0.35%	-0.11%
EBITDA+	0	0	-36.46M	-50.22M	-67.75M	-74.87M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-	-	-0.38%	-0.35%	-0.1%
D&A (Non-Cash Add-back)	4.71M	20.68M	377K	975K	1.11M	1.37M
EBIT	-4.71M	-20.68M	-36.83M	-51.2M	-68.86M	-76.24M
Net Interest Income+	533	0	0	701K	5.2M	5.06M
Interest Income	533	0	0	701K	5.2M	5.06M
Interest Expense	0	0	0	0	0	0
Other Income/Expense	-277K	-10.99M	6.2M	13.51M	4.4M	4.97M
Pretax Income+	-4.99M	-31.67M	-30.64M	-37.69M	-64.47M	-71.27M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-4.99M	-31.67M	-30.64M	-37.69M	-64.47M	-71.27M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-5.35%	0.03%	-0.23%	-0.71%	-0.11%
Net Income (Continuing)	-4.99M	-31.67M	-30.64M	-37.69M	-64.47M	-71.27M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	0.00	-183.08	-26.89	-10.33	-6.18	-4.89
EPS Growth %	-	-	0.85%	0.62%	0.4%	0.21%
EPS (Basic)	0.00	-183.08	-26.89	-10.33	-6.18	-4.89
Diluted Shares Outstanding	176K	172.98K	1.14M	3.65M	10.44M	14.58M
Basic Shares Outstanding	176K	172K	1.14M	3.65M	10.44M	14.58M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	27.16M	20.68M	87.83M	41.73M	88.94M	75.81M
Cash & Short-Term Investments	27.16M	19.84M	84.7M	38.25M	86.89M	71.64M
Cash Only	27.16M	19.84M	84.7M	38.25M	86.89M	71.64M
Short-Term Investments	0	0	0	0	0	0
Accounts Receivable	0	600K	0	0	250K	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	837K	1.87M	309K	646K
Total Non-Current Assets+	48K	2.67M	5.82M	6.63M	5.95M	4.09M
Property, Plant & Equipment	0	2.03M	4.83M	5.45M	4.19M	2.85M
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	417K	417K
Other Non-Current Assets	48K	643K	990K	1.18M	1.34M	820K
Total Assets+	27.21M	23.36M	93.65M	48.36M	94.89M	79.9M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	-0.14%	3.01%	-0.48%	0.96%	-0.16%
Total Current Liabilities+	1.99M	4.01M	8.02M	7.07M	12.37M	15.24M
Accounts Payable	623K	1.42M	3.92M	1.77M	4.15M	4.03M
Days Payables Outstanding	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	0	1.33M	785K	194K	5.49M	3.7M
Current Ratio	13.63x	5.16x	10.95x	5.91x	7.19x	4.98x
Quick Ratio	13.63x	5.16x	10.95x	5.91x	7.19x	4.98x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	4.12M	54.48M	16.12M	5.31M	4.08M	2.99M
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	1.62M	2.38M	2.79M	1.81M	724K
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	4.12M	52.85M	13.74M	2.52M	2.26M	2.26M
Total Liabilities	6.11M	58.49M	24.14M	12.37M	16.45M	18.23M
Total Debt+	0	1.62M	2.88M	3.65M	2.79M	1.81M
Net Debt	-27.16M	-18.21M	-81.82M	-34.6M	-84.1M	-69.82M
Debt / Equity	-	-	0.04x	0.10x	0.04x	0.03x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-
Total Equity+	21.1M	-35.13M	69.52M	35.99M	78.44M	61.67M
Equity Growth %	-	-2.66%	2.98%	-0.48%	1.18%	-0.21%
Book Value per Share	119.90	-203.08	61.01	9.87	7.51	4.23
Total Shareholders' Equity	21.1M	-35.13M	69.52M	35.99M	78.44M	61.67M
Common Stock	10K	1K	4K	0	1K	2K
Retained Earnings	-5.14M	-36.81M	-67.45M	-105.14M	-169.6M	-240.87M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.97M	-18.27M	-33.68M	-45.86M	-52.07M	-62.6M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-8.28%	-0.84%	-0.36%	-0.14%	-0.2%
Net Income	-4.99M	-31.67M	-30.64M	-37.69M	-64.47M	-71.27M
Depreciation & Amortization	0	0	377K	1.31M	1.11M	1.37M
Stock-Based Compensation	6K	1.21M	1.05M	0	5.21M	6.62M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	1.62M	10.9M	-6.09M	-8.83M	976K	502K
Working Capital Changes	1.39M	1.3M	1.62M	-649K	5.1M	173K
Change in Receivables	0	0	600K	-663K	663K	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	0	358K	2.94M	-2.15M	2.38M	-122K
Cash from Investing+	0	0	-2.43M	-576K	-267K	-532K
Capital Expenditures	0	0	-2.43M	-576K	-267K	-552K
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	20K
Cash from Financing+	29.13M	11.29M	100.97M	55K	100.97M	47.88M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	27.63M	53K	90.22M	0	-508K	689K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-1.97M	-18.27M	-36.11M	-46.43M	-52.33M	-63.15M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-8.28%	-0.98%	-0.29%	-0.13%	-0.21%
FCF per Share	-11.19	-105.60	-31.69	-12.73	-5.01	-4.33
FCF Conversion (FCF/Net Income)	0.39x	0.58x	1.10x	1.22x	0.81x	0.88x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-23.63%	-	-178.18%	-71.44%	-112.67%	-101.73%
Debt / Equity	-	-	0.04x	0.10x	0.04x	0.03x
FCF Conversion	0.39x	0.58x	1.10x	1.22x	0.81x	0.88x

Frequently Asked Questions

Growth & Financials

Jasper Therapeutics, Inc. (JSPR) grew revenue by 0.0% over the past year. Growth has been modest.

Jasper Therapeutics, Inc. (JSPR) reported a net loss of $91.0M for fiscal year 2024.

Dividend & Returns

Jasper Therapeutics, Inc. (JSPR) has a return on equity (ROE) of -101.7%. Negative ROE indicates the company is unprofitable.

Jasper Therapeutics, Inc. (JSPR) had negative free cash flow of $76.5M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener